TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18426457

Group type: EXPERIMENTAL
Intervention: Relaxing classical music (Group 1)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Audiobook (Group 2)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No intervention (Control Group 3)
Number of subjects: 94
Study: 15753242

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) combined with pharmacotherapy
Number of subjects: 232

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 232
Study: 12634260

Group type: EXPERIMENTAL
Intervention: Acamprosate (n = 72)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 142
Study: 11388815

Group type: EXPERIMENTAL
Intervention: Home service (automatic transmission of blood pressure data, computerized report forms, weekly electronic transmission)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Home service
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Home service among African-American patients
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care among African-American patients
Number of subjects: 121
Study: 9252945

Group type: EXPERIMENTAL
Intervention: Enteral feeding starting on postoperative day (POD) 1 via a jejunostomy tube (FEED, n = 12)
Number of subjects: 29

Group type: COMPARATOR
Intervention: IV fluid (IVF, n = 17)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Enteral feeding (FEED)
Number of subjects: 29
Study: 8233500

Group type: EXPERIMENTAL
Intervention: Lidocaine with oxymetazoline (lido/oxy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocaine
Number of subjects: 0
Study: 3326920

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg twice daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Captopril plus Nifedipine (50 mg and 20 mg twice daily respectively)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31995558

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional monitoring (CM)
Number of subjects: 50
Study: 31683617

Group type: EXPERIMENTAL
Intervention: Yeast cell wall extract (YCWE) 0.2%
Number of subjects: 168

Group type: COMPARATOR
Intervention: No YCWE (0%)
Number of subjects: 168
Study: 28228696

Group type: EXPERIMENTAL
Intervention: Counseling plus Spinal Manipulation (SM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Counseling alone (Control)
Number of subjects: 10
Study: 25799208

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 937
Study: 23978310

Group type: EXPERIMENTAL
Intervention: Healthy younger adults (N=14)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Older non-fallers (N=14)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Older fallers (N=11)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Older non-fallers and fallers (N=25)
Number of subjects: 39
Study: 21235822

Group type: EXPERIMENTAL
Intervention: Lower levels of oxygen (targeting oxygen saturations of <90%)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Higher levels of oxygen (targeting oxygen saturations of >90%)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Composite outcome of death or major disability at 18 months - 2 years corrected age
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Several measures of neonatal morbidity
Number of subjects: 5000
Study: 19214122

Group type: EXPERIMENTAL
Intervention: 3% SPL7013 gel (n = 24)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo gel (n = 12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SPL7013 gel
Number of subjects: 36
Study: 17237130

Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 1511, target dose 50 mg daily)
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol (n = 1518, target dose 100 mg daily)
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 1511)
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol (n = 1518)
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 3029
Study: 15205083

Group type: EXPERIMENTAL
Intervention: Fe(2+)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fe(3+)
Number of subjects: 72
Study: 11352444

Group type: EXPERIMENTAL
Intervention: Theophylline 400mg alone (Treatment B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theophylline 400mg plus moxifloxacin 200mg (Treatment C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 200mg alone (Treatment A)
Number of subjects: 12
Study: 9797810

Group type: EXPERIMENTAL
Intervention: Three cycles of bleomycin, etoposide, and cisplatin (BEP) for good-risk GCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four cycles of etoposide and cisplatin (EP) for good-risk GCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four cycles of BEP for poor-risk GCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with autologous stem cell rescue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDCT in first-line therapy for poor-risk GCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-resistance
Number of subjects: 0
Study: 7849445

Group type: EXPERIMENTAL
Intervention: 900 mg aspirin daily
Number of subjects: 359

Group type: COMPARATOR
Intervention: 50 mg aspirin daily
Number of subjects: 359
Study: 3053556

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 88
Study: 31209337

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28870554

Group type: COMPARATOR
Intervention: Conventional professional based speech language therapy (SLT) alone (Group A/less intensive)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Conventional professional based speech language therapy (SLT) assisted by computer based language therapy software (Group B/more intensive)
Number of subjects: 24
Study: 25986600

Group type: EXPERIMENTAL
Intervention: Total omega-3 PUFA intake
Number of subjects: 3550

Group type: EXPERIMENTAL
Intervention: α-linolenic acid intake
Number of subjects: 3550

Group type: EXPERIMENTAL
Intervention: Linoleic/α-linolenic ratio
Number of subjects: 3550
Study: 23416804

Group type: EXPERIMENTAL
Intervention: Peppermint oil, administered three times daily for six weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo, administered three times daily for six weeks
Number of subjects: 65
Study: 21809232

Group type: EXPERIMENTAL
Intervention: Nasal packing with breathing tubes
Number of subjects: 73

Group type: COMPARATOR
Intervention: Glove packing
Number of subjects: 73

Group type: COMPARATOR
Intervention: Polyvinyl acetate packing
Number of subjects: 73
Study: 19228414

Group type: EXPERIMENTAL
Intervention: Intensive intervention (patient and physician interventions)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Patient-physician communication behaviors
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Patient ratings of care
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Health service utilization
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 279
Study: 16678595

Group type: EXPERIMENTAL
Intervention: Reduction annuloplasty and coronary artery bypass grafting (RA group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coapsys annuloplasty and bypass grafting (CO group)
Number of subjects: 0
Study: 15673985

Group type: EXPERIMENTAL
Intervention: St. John's wort extract (SJW) 600 mg (standardized to contain 1800 microg of hypericin)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo (containing lactose and cellulose)
Number of subjects: 169
Study: 11408053

Group type: EXPERIMENTAL
Intervention: Dual-task performance in depressed patients prior to antidepressant treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dual-task performance in depressed patients after remission of depression
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dual-task performance in control subjects
Number of subjects: 2
Study: 9203932

Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) at 30 ng/kg/h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK‐A receptor antagonist) at 10 mg/kg/h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Paired saline infusion
Number of subjects: 10
Study: 7869908

Group type: EXPERIMENTAL
Intervention: Delta TSA exceeding 10 mg/dL
Number of subjects: 74

Group type: COMPARATOR
Intervention: Delta TSA not exceeding 10 mg/dL
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Total sialic acid (TSA) levels
Number of subjects: 74
Study: 2081793

Group type: EXPERIMENTAL
Intervention: Oral immune globulin preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard infection control measures
Number of subjects: 0
Study: 367576

Group type: EXPERIMENTAL
Intervention: Combination of vincristine, methyl‐CCNU, and methotrexate with MER‐BCG
Number of subjects: 124

Group type: COMPARATOR
Intervention: Combination of vincristine, methyl‐CCNU, and methotrexate without MER‐BCG
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination of vincristine, methyl‐CCNU, and methotrexate (with or without MER‐BCG)
Number of subjects: 124
Study: 31629881

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive breathing (IRB) test
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnea endurance (IHE) test
Number of subjects: 15
Study: 31657981

Group type: EXPERIMENTAL
Intervention: PEG‐asparaginase 3,500 U/m2
Number of subjects: 598

Group type: COMPARATOR
Intervention: PEG‐asparaginase 2,500 U/m2 (control)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Additional intrathecal therapy (two extra doses)
Number of subjects: 598

Group type: COMPARATOR
Intervention: No additional intrathecal therapy
Number of subjects: 598
Study: 28089917

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D
Number of subjects: 45
Study: 25585167

Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 (ω-3) polyunsaturated fatty acids (PUFAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25406858

Group type: EXPERIMENTAL
Intervention: Usual homecare re‐ablement plus an enhanced program targeted at activities of daily living (ADL), delivered by an occupational therapist.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual homecare re‐ablement (without routine occupational therapy input).
Number of subjects: 50
Study: 22785005

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oxygen therapy (O(2))
Number of subjects: 42
Study: 19637377

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tolterodine ER 8 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 17982551

Group type: COMPARATOR
Intervention: Clearfil Liner Bond 2V ‐ C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT/NRC ‐ PB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single Bond ‐ SB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All Bond 2 ‐ AB
Number of subjects: 40
Study: 16033162

Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 12153960

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micro g once daily (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 26
Study: 10089948

Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidines (o-FPs)
Number of subjects: 4960

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 4960
Study: 8777335

Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch in milk (Test Snack Period)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard Snack Period
Number of subjects: 13
Study: 1847088

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 324

Group type: COMPARATOR
Intervention: Glucose placebo
Number of subjects: 324
Study: 6882723

Group type: EXPERIMENTAL
Intervention: High-protein-low-carbohydrate diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: High-glucose-low-protein diet
Number of subjects: 6
Study: 30207807

Group type: EXPERIMENTAL
Intervention: HP 0.01% lotion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HP 0.05% cream
Number of subjects: 150
Study: 27888748

Group type: EXPERIMENTAL
Intervention: Interpersonal emotion regulation (partner's chosen strategy)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intrapersonal emotion regulation (self-chosen strategy)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cognitive empathy of the regulator
Number of subjects: 47
Study: 25877021

Group type: EXPERIMENTAL
Intervention: 10-mg intramuscular metoclopramide prior to operation
Number of subjects: 696
Study: 22963348

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics injected into the posterior chamber
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intracameral mydriatics injected into the anterior chamber
Number of subjects: 44
Study: 21056445

Group type: EXPERIMENTAL
Intervention: Argemone mexicana (AM)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Artesunate/amodiaquine (ACT)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both AM and ACT
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Total parasite clearance at day 28
Number of subjects: 301
Study: 19207733

Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation at best settings (130 Hz, high voltage)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation at high frequency (> or = 60 Hz)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation with varying pulse widths (60 to 450 micros)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation at 130 Hz
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation overall
Number of subjects: 8
Study: 17113691

Group type: EXPERIMENTAL
Intervention: Conscious analgesia and sedation during orthognathic surgery (study group).
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard procedure without conscious analgesia and sedation (control group).
Number of subjects: 152
Study: 15219269

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol adjustable maintenance dosing (two inhalations bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inhalations once nocte or one inhalation bid if symptoms were controlled)
Number of subjects: 2358

Group type: COMPARATOR
Intervention: Budesonide/formoterol fixed maintenance dosing (two inhalations bid)
Number of subjects: 2358
Study: 11690735

Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg/day
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/day
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg/day and 2400 mg/day
Number of subjects: 334
Study: 1546861

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA, 10 to 15 mg/kg body weight per day) for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 12
Study: 3893793

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29538661

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) and biomarker feedback on secondhand smoke exposure (SHSe) with asthma education, MI, and SHSe feedback plus randomization to six counseling calls (MI; repeated feedback) for 4 months.
Number of subjects: 341

Group type: COMPARATOR
Intervention: Control calls (brief check on asthma) for 4 months.
Number of subjects: 341
Study: 25951368

Group type: EXPERIMENTAL
Intervention: Stop-Only-While-Shocking (SOWS) algorithm
Number of subjects: 29

Group type: COMPARATOR
Intervention: European Resuscitation Council (ERC) 2010 algorithm
Number of subjects: 29
Study: 25911824

Group type: EXPERIMENTAL
Intervention: Child anorexia granule (1 package bid for 1-3 years, 1 package tid for 4-6 years, po, 4 weeks)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Domperidone suspension (0.3 mg x kg(-1) x d(-1), tid, orally 30 minutes before meals)
Number of subjects: 81
Study: 22001231

Group type: COMPARATOR
Intervention: Behavioral interventions
Number of subjects: 46
Study: 20687954

Group type: EXPERIMENTAL
Intervention: Duet cervical barrier used continuously for 14 days
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Duet cervical barrier used precoitally for 14 days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 103
Study: 17917611

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg oral capsules three times daily for 4 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg oral capsules
Number of subjects: 200
Study: 16827248

Group type: EXPERIMENTAL
Intervention: Enflurane with nitrous oxide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Enflurane without nitrous oxide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Age influence
Number of subjects: 48

Group type: COMPARATOR
Intervention: Weight influence
Number of subjects: 48

Group type: COMPARATOR
Intervention: ASA status influence
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gender influence
Number of subjects: 48
Study: 12839718

Group type: EXPERIMENTAL
Intervention: Modified Danger Ideation Reduction Therapy (DIRT)
Number of subjects: 0
Study: 11106211

Group type: EXPERIMENTAL
Intervention: Peak flow manoeuvre (PEFPF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Forced vital capacity manoeuvre (PEFVC)
Number of subjects: 80
Study: 9002088

Group type: EXPERIMENTAL
Intervention: Steep lens fitting protocol
Number of subjects: 30
Study: 1642348

Group type: EXPERIMENTAL
Intervention: Painful stimulation via tetanic electrical stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No painful stimulation (control)
Number of subjects: 0
Study: 3516447

Group type: EXPERIMENTAL
Intervention: Björk-Shiley valve
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Hancock valve
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Carpentier-Edwards valve
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Mitral plus aortic valve replacement
Number of subjects: 540

Group type: COMPARATOR
Intervention: All prostheses
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: All patients with Björk-Shiley prostheses
Number of subjects: 540

Group type: COMPARATOR
Intervention: Reoperation for valve failure
Number of subjects: 540
Study: 29959110

Group type: EXPERIMENTAL
Intervention: Qualitative-only analysis for drug question (n=58)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: NLP analysis for drug question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative and NLP-augmented analysis for drug question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative-only analysis for police question (n=68)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: NLP-only analysis for police question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative and NLP-augmented analysis for police question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: NLP-only approach for drug question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative-only approach for drug question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: NLP-only approach for police question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative-only approach for police question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative analysis followed by qualitative- or NLP-augmented analysis for drug question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: NLP analysis followed by qualitative analysis for drug question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Qualitative analysis followed by qualitative- or NLP-augmented analysis for police question
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: NLP analysis followed by qualitative analysis for police question
Number of subjects: 126
Study: 26849462

Group type: EXPERIMENTAL
Intervention: Second-look endoscopy (SLE)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Non-second-look endoscopy (non-SLE)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both groups (SLE and non-SLE)
Number of subjects: 220
Study: 24141698

Group type: EXPERIMENTAL
Intervention: palonosetron 0.25 or 0.75 mg
Number of subjects: 2962

Group type: COMPARATOR
Intervention: palonosetron 0.25 mg
Number of subjects: 2962

Group type: COMPARATOR
Intervention: palonosetron 0.75 mg
Number of subjects: 2962
Study: 22711895

Group type: EXPERIMENTAL
Intervention: Intranasal ROX-828 (31.5 mg ketorolac tromethamine/200 µL, containing 6% of lidocaine)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (with 6% lidocaine)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intranasal ROX-828
Number of subjects: 140
Study: 21799442

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 19226292

Group type: EXPERIMENTAL
Intervention: MgSO(4).IV
Number of subjects: 40

Group type: COMPARATOR
Intervention: MgSO(4)/L
Number of subjects: 40
Study: 16838873

Group type: EXPERIMENTAL
Intervention: Curvex toothbrush
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral-B Indicator 40 toothbrush
Number of subjects: 21
Study: 12908666

Group type: EXPERIMENTAL
Intervention: New treatment added to existing treatment options
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing treatment options
Number of subjects: 0
Study: 10821991

Group type: EXPERIMENTAL
Intervention: 50 mg of oral carvedilol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25 mg carvedilol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg carvedilol
Number of subjects: 12
Study: 9554136

Group type: EXPERIMENTAL
Intervention: Excimer laser correction using erodible masks
Number of subjects: 83